CoChat
Sign Up
Cited by 184Smoking Behavior and CessationPharmacovigilance and Adverse Drug ReactionsSubstance Abuse Treatment and Outcomes

The DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.

A double-blind study evaluating the long-term safety of varenicline for smoking cessation

Williams, Kathryn E., Reeves, Karen R., Billing, Clare B., Pennington, Ann M., Gong, Jason·2007·Current Medical Research and Opinion
DOI 10.1185/030079907x182185
Open this paper in CoChat — free account

Abstract

OBJECTIVE: We assessed the safety of long-term varenicline administration for smoking cessation. METHODS: In this randomized, double-blind, multicenter trial, eligible adult smokers (18-75 years) who smoked an average of > or =10 cigarettes/day were randomized to either varenicline 1 mg twice daily (BID) or placebo for 52 weeks. Subjects made weekly clinic visits until week 8, and then every 4 weeks until week 52, with a follow-up visit at week 53. The target quit date was the morning of the week 1 clinic visit. Brief counseling was provided at each visit, and vital signs, adverse events (AEs), and smoking status were documented. Other laboratory measures were collected at specified visits. RESULTS: A total of 251 subjects were randomized to varenicline and 126 to placebo. Approximately half of the subjects in each arm completed the study (53.8% varenicline; 46.8% placebo). Treatment-emergent AEs were observed in 96.4% of varenicline- and 82.5% of placebo-treated subjects during the study. Common varenicline-associated AEs were nausea (40.2%), abnormal dreams (22.7%), and insomnia (19.1%). Most AEs were considered mild or moderate in intensity. AEs leading to discontinuation of varenicline treatment included nausea (7.6%), insomnia (3.2%), and abnormal dreams (2.4%). A single varenicline-related serious AE, bilateral subcapsular cataracts, was observed. At week 52, 7-day point prevalence abstinence rates were 36.7% (varenicline) and 7.9% (placebo). CONCLUSIONS: Varenicline 1 mg BID can be safely administered for up to 1 year. Varenicline was also a more effective smoking cessation aid than placebo throughout the study, supporting both its short- (12-week) and long-term (52-week) efficacy.

Overview

Integrity signals

Registry

Crossref · 10.1185/030079907x182185

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 19 references

Research works printed but not linked: 1

  1. 10.1001/jama.1994.03510480064036 · DOI

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Williams, K. E., Reeves, K. R., Billing, C. B., Pennington, A. M., & Gong, J.
Affiliations
Pfizer (United States) (US)
Corresponding author
Williams, Kathryn E.
Venue
Current Medical Research and Opinion
Publisher
Informa Healthcare
Published
2007-03-05
Volume
23
Issue
4
Pages
793-801
ISSN
  • 0300-7995 (ISSN-L)
  • 1473-4877
DOI
10.1185/030079907x182185
OpenAlex
W2133053824
Cited by
184
References
19
Citations by year
2026: 4 · 2025: 3 · 2024: 7 · 2023: 6 · 2022: 6 · 2021: 5 · 2020: 9 · 2019: 4 · 2018: 5 · 2017: 4 · 2016: 14 · 2015: 7 · 2014: 5 · 2013: 7 · 2012: 11
FWCI
15.96
Type
journal article
Language
en
Open access
closed
Locations
  • Current Medical Research and Opinion (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords
varenicline, smoking cessation, long-term safety, adverse events, nausea, insomnia, nicotine dependence, smoking abstinence, nicotine receptor partial agonist
MeSH terms
Varenicline, Smoking Prevention, Adolescent, Adult, Aged, Benzazepines, Double-Blind Method, Female, Humans, Male, Middle Aged, Placebos, Quinoxalines, Time, Time Factors, Smoking Cessation, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review